A large American pharmaceutical company identified that a senior research scientist with access to proprietary drug development data had downloaded and transferred substantial volumes of internal research materials prior to departing the organization. Shortly thereafter, the individual joined a China-based biotechnology enterprise that began developing and marketing a product bearing material similarities to the company’s proprietary formulation under a new commercial name.
Global Data Risk was retained under counsel to lead a cross-border trade secret investigation and manage global eDiscovery strategy. The engagement required structured forensic reconstruction of endpoint activity, cloud repository access, external storage utilization, and encrypted file transfer mechanisms. The investigation focused not only on data movement, but on isolating which datasets constituted protected trade secrets — including formulation data, clinical development strategies, process optimization records, and proprietary research protocols.
GDR designed and managed a defensible eDiscovery workflow spanning multiple custodians and jurisdictions, including preservation, collection, processing, and analytics across high-volume research archives and laboratory documentation systems. Advanced search methodologies and technical filtering were employed to map exfiltrated data against the allegedly replicated product’s development trajectory. The analysis established temporal sequencing demonstrating that critical proprietary information had been accessed and transferred prior to departure.
In parallel, GDR prepared structured expert analysis supporting injunctive relief and trade secret claims, translating complex pharmaceutical research processes into clear, defensible findings suitable for judicial review. The findings strengthened the client’s litigation posture in U.S. proceedings while supporting coordinated strategic considerations involving foreign enforcement risk.
The matter reinforced the importance of disciplined forensic methodology, technical fluency in highly specialized scientific domains, and global litigation support architecture in protecting proprietary pharmaceutical innovation against cross-border misappropriation.
